PMID- 36211543 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20221011 IS - 2297-055X (Print) IS - 2297-055X (Electronic) IS - 2297-055X (Linking) VI - 9 DP - 2022 TI - New adverse coronary events in valve-in-valve TAVR and native TAVR-A 2-year matched cohort. PG - 1004103 LID - 10.3389/fcvm.2022.1004103 [doi] LID - 1004103 AB - OBJECTIVE: To assess the incidence of new adverse coronary events (NACE) following transcatheter aortic valve replacement (TAVR) and valve-in-valve TAVR (ViV-TAVR). BACKGROUND: ViV-TAVR is an accepted treatment for degenerative prostheses among patients with high surgical-risk. TAVR studies have suggested an increased risk of coronary artery obstruction and flow stasis causing thrombus formation. Whether contemporary ViV-TAVR is associated with higher rate of coronary events compared to TAVR is unknown. METHODS: We used data from 1,224 TAVR patients between 2016 and 2021. We propensity-matched patients following ViV-TAVR and TAVR by significant predictors to overcome confounders in patients' baseline characteristics and procedural factors. RESULTS: The matched population included 129 patients in each group. In line with prior reports, there was a higher in-hospital coronary artery obstruction rate with ViV-TAVR (3.1 vs. 1.6%; p = 0.23). Despite this, 2-year cumulative NACE rates were similar between groups (4.7 vs. 6.2%, respectively, p = 0.79), with no difference between its components: myocardial infarction (MI) (p = 0.210), unplanned coronary catheterization (p = 0.477), or coronary artery bypass grafting (CABG) (p = 0.998). Moreover, hypoattenuated leaflets thickening (HALT) at 30-day CT was observed in nearly a quarter of the patients with no difference between groups (23.9 vs. 23.1%, HR 1.02, 95% CI 0.50-1.28, p = 0.872). The progression rate of the coronary artery calcium score (CACS), assessed in a third of patients, was similar between groups (p log-rank = 0.468, 95% CI 0.12-1.24). Low coronary artery height was an unfavorable predictor for in-hospital coronary obstruction and 2-year NACE rate (HR 1.20 and HR 1.25, p = 0.001 and p < 0.0001, respectively). CONCLUSION: At 2-year follow-up, ViV-TAVR was not associated with a higher rate of myocardial infarction, unplanned catheterization, coronary artery bypass grafting, or hypoattenuated leaflet thickening. CI - Copyright (c) 2022 Koren, Patel, Naami, Naami, Nagasaka, Shechter, Natanzon, Kohan, Allison, Lerner, Cheng, Chakravarty, Nakamura, Cheng, Jilaihawi and Makkar. FAU - Koren, Ofir AU - Koren O AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. AD - Bruce Rappaport Faculty of Medicine, Technion Israel Institute of Technology, Haifa, Israel. FAU - Patel, Vivek AU - Patel V AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. FAU - Naami, Robert AU - Naami R AD - Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, OH, United States. FAU - Naami, Edmund AU - Naami E AD - School of Medicine, University of Illinois, Chicago, IL, United States. FAU - Nagasaka, Takashi AU - Nagasaka T AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. AD - The Department of Cardiology, Gunma University Hospital, Gunma, Japan. FAU - Shechter, Alon AU - Shechter A AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. AD - Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. FAU - Natanzon, Sharon Shalom AU - Natanzon SS AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. FAU - Kohan, Siamak AU - Kohan S AD - Internal Medicine, Kaiser Permanente Medical Center, Los Angeles, CA, United States. FAU - Allison, Zev AU - Allison Z AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. FAU - Lerner, Addee AU - Lerner A AD - David Geffen School of Medicine, University of California (UCLA), Los Angeles, Los Angeles, CA, United States. FAU - Cheng, Daniel Eugene AU - Cheng DE AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. FAU - Chakravarty, Tarun AU - Chakravarty T AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. FAU - Nakamura, Mamoo AU - Nakamura M AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. FAU - Cheng, Wen AU - Cheng W AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. FAU - Jilaihawi, Hasan AU - Jilaihawi H AD - Heart Valve Center, NYU Langone Health, New York, NY, United States. FAU - Makkar, Raj R AU - Makkar RR AD - Cedars-Sinai Medical Center, Smidt Heart Institute, Los Angeles, CA, United States. LA - eng PT - Journal Article DEP - 20220921 PL - Switzerland TA - Front Cardiovasc Med JT - Frontiers in cardiovascular medicine JID - 101653388 PMC - PMC9532571 OTO - NOTNLM OT - coronary artery bypass graft (CABG) OT - coronary artery calcium score OT - coronary catheterization OT - long-term outcome assessment OT - myocardial infarction OT - propensity score matching (PSM) OT - transcatheter aortic valve replacement OT - valve-in-valve COIS- Author RM received grant support from Edwards Lifesciences Corporation; he is a consultant for Abbott Vascular, Cordis, and Medtronic and holds equity in Entourage Medical. Author TC is a consultant, proctor, and speaker for Edwards Lifesciences and Medtronic; he is a consultant for Abbott Lifesciences and a consultant and speaker for Boston Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. EDAT- 2022/10/11 06:00 MHDA- 2022/10/11 06:01 PMCR- 2022/01/01 CRDT- 2022/10/10 03:56 PHST- 2022/07/26 00:00 [received] PHST- 2022/08/29 00:00 [accepted] PHST- 2022/10/10 03:56 [entrez] PHST- 2022/10/11 06:00 [pubmed] PHST- 2022/10/11 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - 10.3389/fcvm.2022.1004103 [doi] PST - epublish SO - Front Cardiovasc Med. 2022 Sep 21;9:1004103. doi: 10.3389/fcvm.2022.1004103. eCollection 2022.